澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Tryptamine Therapeutics Ltd

0.034

0.000

成交量：- -

成交额：- -

市值：5,472.33万

市盈率：-8.72

高：0.034

开：0.034

低：0.034

收：0.034

52周最高：0.050

52周最低：0.027

股本：16.10亿

流通股本：8.78亿

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.004

每股收益(LYR):-0.004

净资产收益率：-92.06%

总资产收益率：-45.59%

市净率：9.18

市盈率(LYR):-8.79

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

泰普医疗强化临床开发团队关键人事任命助推TRP-8803研发进程

华尔街洞察

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/TYP.AU"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TYP.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TYP.AU\",,,,,undefined,":{"symbol":"TYP.AU","market":"AU","secType":"STK","nameCN":"Tryptamine Therapeutics Ltd","latestPrice":0.034,"timestamp":1770613200000,"preClose":0.034,"halted":8,"volume":0,"delay":0,"changeRate":0,"nameEN":"Tryptamine Therapeutics Ltd","floatShares":878046607,"shares":1609510143,"eps":-0.0039,"marketStatus":"已收盘","change":0,"latestTime":"02-09 16:00:00 AEDT","open":0.034,"high":0.034,"low":0.034,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0039,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1770678000000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.034,"openAndCloseTimeList":[[1770591600000,1770613200000]],"volumeRatio":0,"lotSize":0,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TYP.AU\",,,,,undefined,":{"symbol":"TYP.AU","floatShares":878046607,"roa":"-45.59%","roe":"-92.06%","lyrEps":-0.003868,"shares":1609510143,"dividePrice":0,"high":0.034,"amplitude":0,"preClose":0.034,"low":0.034,"week52Low":0.027,"pbRate":"9.18","psRate":"34.60","week52High":0.05,"institutionHeld":0,"latestPrice":0.034,"eps":-0.0039,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.0039,"open":0.034},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TYP.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-11-21","symbol":"TYP.AU","oldSymbol":"TYP","defaultRemindTime":1763679600000,"newSymbol":"ENP.AU","exchange":"ASX","type":"symbolChange","dateTimestamp":1763643600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TYP.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TYP.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1129418081","title":"泰普医疗强化临床开发团队 关键人事任命助推TRP-8803研发进程","url":"https://stock-news.laohu8.com/highlight/detail?id=1129418081","media":"华尔街洞察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129418081?lang=zh_cn&edition=fundamental","pubTime":"2025-07-16 07:15","pubTimestamp":1752621326,"startTime":"0","endTime":"0","summary":"澳大利亚生物医药企业泰普医疗近日宣布关键人事变动，旨在加速其核心候选药物TRP-8803的临床开发进程。市场分析人士指出，此次人事布局正值TRP-8803准备进入Ⅱb期临床试验的关键节点。团队将着力优化TRP-8803的临床开发策略，最大限度释放该候选药物的治疗潜力。根据最新研发时间表，TRP-8803的剂量扩展研究预计将于2026年第一季度完成患者入组。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","TYP.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/TYP.AU\",params:#limit:6,delay:true,,,undefined,":[]}}